Yue Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yue Lin has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Fuzhou Hua
The Second Affiliated Hospital, Jiangxi Medical College, Nanchang University
20 shared publications - Gen Wei
Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China
19 shared publications - Jiali Song
Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China
19 shared publications - Jun Ying
Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, China
19 shared publications - Longshan Li
Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China
19 shared publications - Luojia Wu
Department of Anesthesiology, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, P.R. China
19 shared publications
Latest Publications
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1, 2 and Table 1,2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1, 2 and Table 1,2
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1, 2 and Table 1,2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1, 2 and Table 1,2
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary table 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- Open Access
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Data from FOXN Transcription Factors: Regulation and Significant Role in Cancer
A growing number of studies have demonstrated that cancer development is closely linked to abnormal gene expression, including alterations in the transcriptional activity of transcription factors. The Forkhead box class N (FOXN) proteins FOXN1–6 form a highly conserved class of transcription factors, which have been shown in recent years to be involved in the regulation of malignant progression in a variety of cancers. FOXNs mediate cell proliferation, cell-cycle progression, cell differentiation, metabolic homeostasis, embryonic development, DNA damage repair, tumor angiogenesis, and other critical biological processes. Therefore, transcriptional dysregulation of FOXNs can directly affect cellular physiology and promote cancer development. Numerous studies have demonstrated that the transcriptional activity of FOXNs is regulated by protein–protein interactions, microRNAs (miRNA), and posttranslational modifications (PTM). However, the mechanisms underlying the molecular regulation of FOXNs in cancer development are unclear. Here, we reviewed the molecular regulatory mechanisms of FOXNs expression and activity, their role in the malignant progression of tumors, and their value for clinical applications in cancer therapy. This review may help design experimental studies involving FOXN transcription factors, and enhance their therapeutic potential as antitumor targets.
- 27 November 2025
- Published by American Association for Cancer Research (AACR)
Open AccessData from FOXN Transcription Factors: Regulation and Significant Role in Cancer
A growing number of studies have demonstrated that cancer development is closely linked to abnormal gene expression, including alterations in the transcriptional activity of transcription factors. The Forkhead box class N (FOXN) proteins FOXN1–6 form a highly conserved class of transcription factors, which have been shown in recent years to be involved in the regulation of malignant progression in a variety of cancers. FOXNs mediate cell proliferation, cell-cycle progression, cell differentiation, metabolic homeostasis, embryonic development, DNA damage repair, tumor angiogenesis, and other critical biological processes. Therefore, transcriptional dysregulation of FOXNs can directly affect cellular physiology and promote cancer development. Numerous studies have demonstrated that the transcriptional activity of FOXNs is regulated by protein–protein interactions, microRNAs (miRNA), and posttranslational modifications (PTM). However, the mechanisms underlying the molecular regulation of FOXNs in cancer development are unclear. Here, we reviewed the molecular regulatory mechanisms of FOXNs expression and activity, their role in the malignant progression of tumors, and their value for clinical applications in cancer therapy. This review may help design experimental studies involving FOXN transcription factors, and enhance their therapeutic potential as antitumor targets.
- 21 November 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (2) , 148-158
IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Interleukin 35(IL-35) is a newly discovered inhibitory cytokine of the IL12 family. More recently, IL-35 was found to be increased in the tumor microenvironment (TME) and peripheral blood of many patients with cancer, indicating that it plays an important role in the TME. Tumors secrete cytokines that recruit myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg) into the TME to promote malignant progression, which is a great challenge for cancer treatment. Radiotherapy causes serious adverse effects, and tumor resistance to immune checkpoint inhibitors is still an unsolved challenge. Thus, new cancer therapy approaches are urgently needed. Numerous studies have shown that IL-35 can recruit immunosuppressive cells to enable tumor immune escape by promoting the conversion of immune cells into a tumor growth–promoting phenotype as well as facilitating tumor angiogenesis. IL-35-neutralizing antibodies were found to boost the chemotherapeutic effect of gemcitabine and considerably reduce the microvascular density of pancreatic cancer in mice. Therefore, targeting IL-35 in the TME provides a promising cancer treatment target. In addition, IL-35 may be used as an independent prognostic factor for some tumors in the near future. This review intends to reveal the interplay of IL-35 with immune cells in the TME, which may provide new options for the treatment of cancer.
- 21 November 2023
- Published by American Association for Cancer Research (AACR) in Molecular Cancer Therapeutics
- Vol. 23 (2) , 148-158
IL-35: New Target for Immunotherapy Targeting the Tumor Microenvironment
Interleukin 35(IL-35) is a newly discovered inhibitory cytokine of the IL12 family. More recently, IL-35 was found to be increased in the tumor microenvironment (TME) and peripheral blood of many patients with cancer, indicating that it plays an important role in the TME. Tumors secrete cytokines that recruit myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Treg) into the TME to promote malignant progression, which is a great challenge for cancer treatment. Radiotherapy causes serious adverse effects, and tumor resistance to immune checkpoint inhibitors is still an unsolved challenge. Thus, new cancer therapy approaches are urgently needed. Numerous studies have shown that IL-35 can recruit immunosuppressive cells to enable tumor immune escape by promoting the conversion of immune cells into a tumor growth–promoting phenotype as well as facilitating tumor angiogenesis. IL-35-neutralizing antibodies were found to boost the chemotherapeutic effect of gemcitabine and considerably reduce the microvascular density of pancreatic cancer in mice. Therefore, targeting IL-35 in the TME provides a promising cancer treatment target. In addition, IL-35 may be used as an independent prognostic factor for some tumors in the near future. This review intends to reveal the interplay of IL-35 with immune cells in the TME, which may provide new options for the treatment of cancer.
- Open Access
- 6 September 2023
- Published by American Association for Cancer Research (AACR)
Data from FOXN Transcription Factors: Regulation and Significant Role in Cancer
A growing number of studies have demonstrated that cancer development is closely linked to abnormal gene expression, including alterations in the transcriptional activity of transcription factors. The Forkhead box class N (FOXN) proteins FOXN1–6 form a highly conserved class of transcription factors, which have been shown in recent years to be involved in the regulation of malignant progression in a variety of cancers. FOXNs mediate cell proliferation, cell-cycle progression, cell differentiation, metabolic homeostasis, embryonic development, DNA damage repair, tumor angiogenesis, and other critical biological processes. Therefore, transcriptional dysregulation of FOXNs can directly affect cellular physiology and promote cancer development. Numerous studies have demonstrated that the transcriptional activity of FOXNs is regulated by protein–protein interactions, microRNAs (miRNA), and posttranslational modifications (PTM). However, the mechanisms underlying the molecular regulation of FOXNs in cancer development are unclear. Here, we reviewed the molecular regulatory mechanisms of FOXNs expression and activity, their role in the malignant progression of tumors, and their value for clinical applications in cancer therapy. This review may help design experimental studies involving FOXN transcription factors, and enhance their therapeutic potential as antitumor targets.
- 6 September 2023
- Published by American Association for Cancer Research (AACR)
Open AccessData from FOXN Transcription Factors: Regulation and Significant Role in Cancer
A growing number of studies have demonstrated that cancer development is closely linked to abnormal gene expression, including alterations in the transcriptional activity of transcription factors. The Forkhead box class N (FOXN) proteins FOXN1–6 form a highly conserved class of transcription factors, which have been shown in recent years to be involved in the regulation of malignant progression in a variety of cancers. FOXNs mediate cell proliferation, cell-cycle progression, cell differentiation, metabolic homeostasis, embryonic development, DNA damage repair, tumor angiogenesis, and other critical biological processes. Therefore, transcriptional dysregulation of FOXNs can directly affect cellular physiology and promote cancer development. Numerous studies have demonstrated that the transcriptional activity of FOXNs is regulated by protein–protein interactions, microRNAs (miRNA), and posttranslational modifications (PTM). However, the mechanisms underlying the molecular regulation of FOXNs in cancer development are unclear. Here, we reviewed the molecular regulatory mechanisms of FOXNs expression and activity, their role in the malignant progression of tumors, and their value for clinical applications in cancer therapy. This review may help design experimental studies involving FOXN transcription factors, and enhance their therapeutic potential as antitumor targets.
- Open Access
- 11 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary table 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 11 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary table 2 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- Open Access
- 11 August 2023
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
- 11 August 2023
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer
Supplementary Figure 1 from FOXN Transcription Factors: Regulation and Significant Role in Cancer